Introduction {#s1}
============

Diabetes mellitus currently affects 25.8 million Americans ([@B1]). Obesity, which typically precedes diabetes, results in altered glucose control. Indeed, adiposity has been implicated in the etiology of insulin resistance, where lipid moieties from the white adipose tissue (WAT) depots disrupt insulin signaling.

Adult humans have recently been shown to have brown adipose tissue (BAT) ([@B2]--[@B4]). Further, BAT is associated with leanness ([@B5]) and euglycemia ([@B4],[@B6],[@B7]), suggesting that, unlike other adipose tissue depots, BAT may be protective against obesity and diabetes. The unique feature of BAT that explains the proposed effects on obesity and glucose control is the abundance of mitochondria, which contain uncoupling protein 1 (UCP1). UCP1 uncouples oxidative phosphorylation by allowing protons to re-enter the mitochondrial matrix independent of ATP synthase, producing heat instead of chemical energy ([@B8]). Rodent studies show that, upon stimulation, BAT uses glucose and free fatty acids (FFAs) for thermogenesis ([@B8]), confirming the regulatory role of BAT in adiposity, glucose homeostasis, and insulin sensitivity ([@B9],[@B10]).

The physiological significance of BAT activation in whole-body substrate metabolism in humans remains unclear. Orava et al. ([@B11]) reported that cold exposure (CE) resulted in a 12-fold increase in glucose disposal in BAT, but not in other tissues. Ouellet et al. ([@B12]) reported similar results. This suggests that, upon activation, BAT clears plasma glucose. However, these investigators did not show differences in whole-body insulin-stimulated glucose disposal between individuals with detectable BAT (BAT^+^) or nondetectable BAT (BAT^−^), questioning the ability of BAT to modulate whole-body glucose metabolism. Similarly, Ouellet et al. ([@B12]) recently showed that under short-term CE, BAT primarily oxidizes intracellular fatty acids; plasma substrate oxidation by BAT was minimal ([@B12]).

The results from the aforementioned studies question the role of BAT in whole-body metabolism in humans. However, Orava et al. ([@B11],[@B13]) compared whole-body insulin-stimulated glucose disposal between BAT^+^ and BAT^−^ groups under thermoneutral (TN) conditions. The role of BAT in whole-body glucose metabolism is likely more readily discerned when BAT is activated. Furthermore, Ouellet et al. ([@B12]) demonstrated that BAT minimally contributed to whole-body plasma glucose utilization, which might be due to the shorter duration of CE and the presence of mild shivering. Animal studies ([@B8]) suggest that BAT first consumes intracellular energy stores before using plasma-borne substrates to support its energy needs. Subsequently, a longer CE may be necessary to elucidate the role of BAT activation in plasma glucose disposal and oxidation in humans.

The aim of this study was to investigate the effect of prolonged (5--8 h) cold-induced BAT activation on the whole-body glucose metabolism. Twelve men (7 BAT^+^ and 5 BAT^−^) were studied under CE and TN conditions. CE increased resting energy expenditure (REE), plasma glucose oxidation, and whole-body insulin-stimulated glucose disposal in the BAT^+^ individuals only. The current data support a physiologically significant role for BAT in whole-body glucose homeostasis and insulin sensitivity in humans.

Research Design and Methods {#s2}
===========================

Subjects {#s3}
--------

Twelve males participated in the study. The participants were screened for health status, smoking, alcohol or drug use, and recent medication or supplement use. Only healthy individuals qualified to participate in the study. Informed written consent was obtained from all participants prior to their inclusion in the study in accordance with the Declaration of Helsinki. The University of Texas Medical Branch and Institute for Translational Sciences Institutional Review Boards approved the experimental protocol.

Experimental Protocol {#s4}
---------------------

Each participant completed one CE study and one TN study, 2 weeks apart ([Fig. 1](#F1){ref-type="fig"}). The CE trial was performed first to determine BAT volume and anatomical location using 2-deoxy-2-\[^18^F\]-fluoro-[d]{.smallcaps}-glucose (^18^F-FDG) positron emission tomography (PET)/computed tomography (CT) scanning.

![Study design. The following tracers infused: \[6,6-^2^H~2~\]-glucose, \[U-^13^C~16~\] palmitate, and ^13^C sodium bicarbonate. IC, indirect calorimetry.](4089fig1){#F1}

Three days before each study, subjects followed a weight-maintaining diet and refrained from physical activity and the consumption of alcohol and caffeine. The evening before the study, subjects were admitted to the Institute for Translational Sciences-Clinical Research Center at the University of Texas Medical Branch. Patients were fed a standardized evening meal. During CE and TN studies, subjects were fasted overnight and remained rested in bed for the duration of the study. Subjects wore standardized clothing (T-shirt and shorts).

CE Protocol and TN Conditions {#s5}
-----------------------------

We used the following individualized CE protocol to maximize nonshivering thermogenesis; subjects were studied in a room with an ambient temperature of ∼19°C and wearing garments cooled by liquid circulation (Cool Flow vest and blanket; Polar Products Inc., Stow, Ohio). The temperature of the vest was initially set at 20°C, then decreased at 1°C intervals through an air-conditioned temperature control bath (Chiller Reservoir System; Polar Products Inc.) until subjects reported shivering. Then the temperature was increased by 1°C and was maintained at a constant temperature. We visually inspected the subjects for shivering. In a subset of individuals (*n* = 3), we performed electromyography (Bagnoli 8; Delsys, Boston, MA) at 5-min intervals to verify muscle activity ([@B14]). Core temperature and skin temperature were measured using a telemetric pill (Core-Temp; HQ Inc., Palmetto, FL) and wireless probes (iButtons; Maxim Integrated Products, Dallas, TX) ([@B15]), respectively.

Stable Isotope Infusion {#s6}
-----------------------

After 3 h of either the CE or the TN study, blood was sampled to determine background enrichment, prior to the administration of the following stable isotope tracers (Cambridge Isotope Laboratories, Andover, MA) through a catheter in the forearm vein, as follows: *1*) a primed (17.6 μmol/kg), constant (0.22 μmol/kg/min) 2-h infusion of \[6,6-^2^H~2~\]-glucose to assess glucose kinetics ([@B16]); *2*) a constant 2-h infusion of potassium \[U-^13^C~16~\]-palmitate (0.02 μmol/kg/min) to assess FFA kinetics ([@B17],[@B18]); and *3*) a bolus of NaH^13^CO~3~ (55 μmol/kg dissolved in 0.9% NaCl) was also given to prime the body's bicarbonate pool. Blood and breath samples were obtained at 1 h and 50 min, 1 h and 55 min, and 2 h after the initiation of the stable isotope infusion to determine isotopic enrichments of plasma glucose and palmitate, and breath CO~2~, and to measure substrate concentrations. The same regimen, including only \[6,6-^2^H~2~\]-glucose, was repeated during the hyperinsulinemic-euglycemic clamp. Whole-body glucose disposal and FFA oxidation were calculated as previously described ([@B19],[@B20]). Changes between CE and TN in glucose uptake were calculated as the difference between the glucose uptake in CE and TN conditions.

Hyperinsulinemic-Euglycemic Clamp {#s7}
---------------------------------

Hyperinsulinemic-euglycemic clamps were conducted during the last 2 h of each trial, as previously described ([@B21]). Insulin (Lilly, Indianapolis, IN) was administered at a rate of 20 mU/m^2^/min, dissolved in sterile NaCl 0.9% ([@B19]). We used a low insulin infusion rate to avoid the stimulation of muscle plasma glucose disposal ([@B22]). Whole-body insulin-stimulated glucose disposal was evaluated using the insulin sensitivity index ([@B23]) and the following formula: glucose disposal (in micromoles per kilogram per minutes)/steady-state plasma glucose (in milligrams per deciliter) ([@B24]).

PET/CT Scanning {#s8}
---------------

After 5 h, subjects were injected with a bolus of 185 MBq ^18^F-FDG. We performed a PET/CT scan (GE Discovery ST 4 Slice scanner; General Electric, Milwaukee, WI) an hour later to assess BAT volume and BAT glucose disposal (BAT volume \[in milliliters\] × mean standardized disposal value \[SUV; in grams per milliliter\]). An independent blinded investigator assessed the PET/CT scans for BAT, as previously described ([@B12]). Subjects with pronounced ^18^F-FDG disposal were assigned to the BAT^+^ group (*n* = 7; BAT volume 69 ± 18 mL) ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0746/-/DC1)), while subjects with no or minimal ^18^F-FDG disposal were assigned to the BAT^−^ group (*n* = 5; BAT volume 4.4 ± 2.3 mL; *P* \< 0.05) ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0746/-/DC1)).

Body Composition {#s9}
----------------

DEXA (Lunar iDXA\*; GE Healthcare, Mickleton, NJ) was used to evaluate the lean and fat body mass of the participants. CT was used to estimate total, subcutaneous, and visceral abdominal tissue area ([@B25]--[@B27]).

Indirect Calorimetry {#s10}
--------------------

REE was calculated using whole-body oxygen consumption and carbon dioxide production rates measured by indirect calorimetry (Vmax Encore; CareFusion Corporation, San Diego, CA) ([@B28]). Indirect calorimetry equipment failed on two occasions (one BAT^+^ subject and one BAT^−^ subject).

Blood Samples Analysis {#s11}
----------------------

Plasma glucose concentrations were determined using an automated glucose analyzer (Stat 2300; Yellow Spring Instruments). Gas chromatography mass spectrometry was used to quantify plasma enrichments of glucose and palmitate (Agilent, Santa Clara, CA). Plasma insulin and free triiodothyronine (FT3) concentrations were measured using chemiluminescence (Dxi 600 analyzer; Beckman Coulter, Pasadena, CA). Free thyroxine (FT4) was measured via a quantitative electrochemiluminescent immunoassay (ARUP, Salt Lake City, UT). Plasma norepinephrine level was determined using quantitative high-performance liquid chromatography (ARUP, Salt Lake City, UT). Further, serum interleukin-6 (IL-6) (R&D Systems, Minneapolis, MN), plasma irisin (Phoenix Pharmaceuticals, Burlingame, CA), and fibroblast growth factor 21 (FGF21) (BioVendor, Asheville, NC) concentrations were determined using commercially available ELISA kits.

Adipose Tissue Sampling {#s12}
-----------------------

During CE, adipose tissue samples from the supraclavicular and abdominal areas were obtained using a Bergström needle. In a subset of individuals (three BAT^+^ and one BAT^−^ individuals), biopsy samples were obtained during both the CE and TN trials. The location for the supraclavicular biopsy was determined by the ^18^F-FDG PET/CT scan images showing cold-activated BAT. In BAT^−^ individuals, the supraclavicular depot was sampled 2--3 cm from the skin surface area, which is the same depth that the BAT depot has been localized in BAT^+^ individuals. Each sample was divided into pieces for the analyses described below.

### Immunohistochemistry {#s13}

Adipose tissue, preserved in 10% formalin, was embedded in paraffin wax. Immunohistochemistry was performed using a standard protocol ([@B29]). Briefly, after blocking (Rabbit IgG kit; Vector Laboratories, Burlingame, CA) for 45 min, sections were incubated overnight with primary antibody (1:1,600, rabbit anti-UCP1 antibody, U6382; Sigma-Aldrich) at 4°C. Sections were incubated with secondary antibody (rabbit IgG; Vector Laboratories), ABC solution, and then a diaminobenzidine solution (DAB peroxidase substrate kit; Vector Laboratories) at room temperature.

### Mitochondrial Respiration {#s14}

Mitochondrial function was determined by high-resolution respirometry ([@B30]). Briefly, maximal uncoupled mitochondrial respiration was measured in permeabilized (5 µmol/L digitonin) WAT (∼50 mg) and BAT (∼10 mg) after the addition of substrates (1.5 mmol/L octanoyl-carnitine, 5 mmol/L pyruvate, 10 mmol/L glutamate, 2 mmol/L malate, 5 mmol/L ADP, and 10 mmol/L succinate) and the ATP synthase inhibitor oligomycin (5 µmol/L).

### Gene Expression {#s15}

Total RNA was isolated, and cDNA was synthesized and analyzed by quantitative real-time PCR, as previously described ([@B2]), using gene-specific primers at a final concentration of 300 nmol/L ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0746/-/DC1)). 18S was used as the normalizing gene and an established supraclavicular BAT sample was included as a positive control for BAT ([@B2]).

Statistical Analysis {#s16}
--------------------

Results are presented as means ± SEM/SD. Differences between CE and TN trials were evaluated using paired *t* tests for normally distributed data. Non-normally distributed data were evaluated using a Wilcoxon rank sum test. A one-sample *t* test was used to evaluate whether CE induced changes in the various metabolic measurements compared with TN. Differences between BAT^−^ and BAT^+^ subjects were evaluated using a Mann-Whitney *U* test.

To evaluate differences in the circulating levels of the various hormones/cytokines, we used a mixed ANOVA model. Treatment differences (CE-TN) in the levels of hormones/cytokines were determined for each subject at each time point, accounting for the paired within-subject correlation between treatments. A mixed ANOVA modeled the differences as a function of time and BAT status, an autoregressive model of order 1 correlation structure accounted for by the within-subject repeated measures over time, and a weighting structure adjusted for heterogeneity of variance over time. Differences were transformed as needed to better approximate normal distributions, with results inverse transformed appropriately. Statistical analyses were performed using GraphPad, version 5 (GraphPad Software, La Jolla, CA) for the Mac OS X operating system and R statistical software (R Core Team, 2013, version 3.0.1). All statistical tests assumed a 95% level of confidence.

Results {#s17}
=======

By design, the BAT^+^ group had higher BAT volume and activity (*P* \< 0.05) than the BAT^−^ group, but they were similar in age and anthropometric characteristics ([Table 1](#T1){ref-type="table"}). BAT^+^ individuals required slightly, but not significantly, lower ambient and garment temperatures to reach their nonshivering threshold ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0746/-/DC1)). CE decreased skin temperature in both groups (*P* \< 0.05). The BAT^−^ group had a marginally lower core temperature during CE conditions compared with that during TN conditions (*P* = 0.06).

###### 

Subject characteristics

  Parameters                                             BAT^−^ (*n* = 5)   BAT^+^ (*n* = 7)
  ------------------------------------------------------ ------------------ ----------------------------------------------
  Age (years)                                            49.8 ± 7.3         41.2 ± 5.3
  BMI (kg/m)                                             30.0 ± 2.8         28.2 ± 1.5
  BSA (m^2^)                                             2.1 ± 0.1          2.0 ± 0.1
  Lean mass (kg)                                         58.8 ± 3.4         58.3 ± 3.7
  Body fat (%)                                           32.3 ± 22.7        31.3 ± 3.2
  Visceral adipose tissue (cm^2^)                        57.8 ± 12.2        41.9 ± 8.4
  Subcutaneous adipose tissue (cm^2^)                    90.0 ± 22.7        94.3 ± 12.0
  BAT volume (mL)                                        4.4 ± 2.3          69.0 ± 18.0[\*](#t1n1){ref-type="table-fn"}
  BAT activity (BAT volume \[mL\] × mean SUV \[g/mL\])   9.3 ± 4.4          153.2 ± 42.6[\*](#t1n1){ref-type="table-fn"}
  AUC~glu~ (mg/dL)                                       296.3 ± 15.6       248.5 ± 25.6

Data are mean ± SEM.

AUC~glu,~ glucose area under the curve; BSA, body surface area.

\**P* \< 0.05.

BAT Activation Increases Energy Expenditure and Plasma Substrate Oxidation {#s18}
--------------------------------------------------------------------------

Indirect calorimetry and stable isotopes were used to determine REE and substrate oxidation rates. CE increased REE (15%) in the BAT^+^ group only (*P* \< 0.05) ([Fig. 2*A*](#F2){ref-type="fig"}), suggesting that BAT activation increases REE during nonshivering CE. The cold-induced increase in REE in the BAT^+^ group was fueled primarily by plasma-derived glucose and FFA oxidation (*P* \< 0.05 for both) ([Fig. 2*B* and *C*](#F2){ref-type="fig"}). Plasma glucose and FFA contributed ∼30% and 70%, respectively, to the observed increase in REE in the BAT^+^ group. These data suggest that, upon prolonged stimulation, BAT largely oxidizes plasma substrates to support its energy demands. This finding supports a role for BAT in the regulation of systemic glucose and FFA metabolism.

![The role of BAT in REE and substrate oxidation. *A*: REE upon CE and TN conditions in BAT^+^ subjects and BAT^−^ subjects. *B*: Plasma glucose oxidation under CE and TN conditions in BAT^+^ and BAT^−^ subjects. *C*: Plasma FFA oxidation under CE and TN conditions in BAT^+^ and BAT^−^ subjects. White bars, TN; black bars, CE. Data are mean ± SEM. \**P* \< 0.05, CE vs. TN.](4089fig2){#F2}

Glucose Disposal During CE Occurs Primarily in BAT {#s19}
--------------------------------------------------

^18^F-FDG uptake during CE increased significantly in BAT (*P* \< 0.05), but not in the liver, abdominal visceral adipose tissue, abdominal subcutaneous adipose tissue, or skeletal muscle (vastus lateralis and pectoralis) ([Fig. 3](#F3){ref-type="fig"}). Interestingly, the mean heart SUV decreased significantly with CE in BAT^+^ subjects (*P* \< 0.05). In agreement with previous reports ([@B11],[@B12]), our data suggest that mild CE results in increased disposal of labeled glucose by BAT only, with minimal or no effects in other tissues.

![Mean SUV for glucose of various tissues during CE and TN conditions. SQAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; white bars, TN; black bars, CE. Data are mean ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, CE vs. TN.](4089fig3){#F3}

BAT Activation Increases Basal Whole-Body Glucose Disposal {#s20}
----------------------------------------------------------

To determine the physiological significance of BAT activation on whole-body glucose metabolism, we assessed glucose kinetics during TN conditions and during prolonged (5 h) CE. CE significantly increased whole-body glucose disposal only in the BAT^+^ group (*P* \< 0.05) ([Table 2](#T2){ref-type="table"}, [Fig. 4*A*](#F4){ref-type="fig"}). Theoretically, if BAT remained chronically active, it could dispose ∼23 g of glucose in 24 h. Combined with the PET/CT scan data, showing that ^18^F-FDG uptake increased only in BAT ([Fig. 3](#F3){ref-type="fig"}), these data suggest that, when activated, BAT has the ability to take up significant amounts of glucose from the circulation, and therefore can play a significant role in glycemic control.

###### 

Indices of whole-body glucose homeostasis under CE and TN conditions

  Parameters                                          BAT^−^ (*n* = 5)   BAT^+^ (*n* = 7)                                               
  --------------------------------------------------- ------------------ ------------------ ------------------------------------------- ----------------------------------------------------------------------------
  Basal conditions                                                                                                                      
   Glucose (mg/mL)                                    90.0 ± 7.9         94.0 ± 3.4         93.4 ± 2.0                                  89.5 ± 3.2
   Whole-body glucose disposal (μmol/kg/min)          9.4 ± 0.7          9.7 ± 0.6          10.2 ± 0.5                                  11.6 ± 0.2[\*](#t2n1){ref-type="table-fn"}
   Insulin (μU/mL)                                    8.6 ± 4.0          8.2 ± 1.3          3.9 ± 0.8[†](#t2n2){ref-type="table-fn"}    3.8 ± 1.0[†](#t2n2){ref-type="table-fn"}
  Hyperinsulinemic-euglycemic conditions                                                                                                
   Glucose (mg/mL)                                    83.8 ± 3.1         85.8 ± 3.5         81.1 ± 3.3                                  81.5 ± 5.8
   Whole-body glucose disposal (μmol/kg/min)          12.4 ± 2.2‡        12.8 ± 1.8         13.0 ± 0.9[‡](#t2n3){ref-type="table-fn"}   16.5 ± 1.1[\*](#t2n1){ref-type="table-fn"},[‡](#t2n3){ref-type="table-fn"}
   Endogenous glucose production (μmol/kg/min)        5.6 ± 1.6          7.5 ± 1.1          5.3 ± 1.7                                   6.3 ± 1.3
   Suppression of endogenous glucose production (%)   −59.7 ± 9.4        −48.2 ± 6.9        −62.4 ± 12.5                                −59.1 ± 9.1
   Insulin (μU/mL)                                    33.5 ± 4.3         31.0 ± 6.7         18.2 ± 2.0[†](#t2n2){ref-type="table-fn"}   18.8 ± 2.0

Data are mean ± SEM.

\**P* \< 0.05, CE vs. TN conditions.

†*P* \< 0.05, BAT^−^ vs. BAT^+^ subjects.

‡*P* \< 0.05, basal vs. hyperinsulinemic-euglycemic conditions.

![Effect of BAT on whole-body glucose disposal and insulin sensitivity. Change in whole-body glucose disposal under CE relative to TN in basal condition (*A*) and during hyperinsulinemic-euglycemic clamp (*B*). *C*: Change in the insulin sensitivity index (ISI) for CE and TN. *D*: Change in whole-body insulin sensitivity for CE relative to TN. Data are means ± SEM. White bars, BAT^−^; black bars, BAT^+^. \**P* \< 0.05 and \*\**P* \< 0.01, significant change with CE vs. TN conditions. †*P* \< 0.05, BAT^+^ vs. BAT^−^.](4089fig4){#F4}

BAT Activation Increases Insulin-Stimulated Whole-Body Glucose Disposal {#s21}
-----------------------------------------------------------------------

Under thermoneutrality, insulin infusion significantly increased whole-body glucose disposal in both groups (*P* \< 0.05 for both) ([Table 2](#T2){ref-type="table"}). This increase reflects increased glucose disposal in many tissues and indicates that the two groups were sensitive to insulin in peripheral tissues (i.e., skeletal muscle, WAT), even though the BAT^−^ group needed higher insulin levels to achieve the same result (i.e., slightly less insulin sensitive). Further, insulin infusion suppressed endogenous glucose production similarly in both groups (*P* \< 0.05), indicating that both groups were sensitive to insulin at the level of the liver.

After establishing that both groups were responsive to insulin, we determined the effect of cold-induced BAT activation on glucose disposal during hyperinsulinemia (resembling the postprandial state). To this end, we infused insulin after 6 h of CE. Compared with the insulin-induced increase in glucose disposal in thermoneutrality, CE further increased glucose disposal in the BAT^+^ group only (*P* \< 0.05) ([Table 2](#T2){ref-type="table"}, [Fig. 4*B*](#F4){ref-type="fig"}). The results were similar when the whole-body glucose disposal rates were corrected for glucose levels (whole-body insulin sensitivity index) ([Fig. 4*C*](#F4){ref-type="fig"}) or in combination with insulin concentration (insulin sensitivity index) ([Fig. 4*D*](#F4){ref-type="fig"}). Finally, hyperinsulinemia equally suppressed endogenous glucose production in both groups under CE conditions (*P* \< 0.05). These findings suggest that BAT activation may play a functional role in peripheral glucose disposal, both in the postabsorptive and postprandial state.

BAT Status and Hormonal/Cytokine Response to Cold {#s22}
-------------------------------------------------

Our study was not designed to examine the mechanisms regulating the effect of BAT activation on glucose metabolism. Nevertheless, we measured the levels of FT3, FT4, FGF21, cytokines (irisin, leptin, IL-6), and norepinephrine, which have been previously associated with BAT activation ([@B8],[@B10],[@B30],[@B31]). The BAT^+^ group demonstrated higher increases in the circulating concentrations of norepinephrine, FGF21, and FT3, when compared with the BAT^−^ group ([Fig. 5*A*--*C*](#F5){ref-type="fig"}). FT4, irisin, and IL-6 levels were not significantly different between the two groups ([Fig. 5*D*--*F*](#F5){ref-type="fig"}).

![Change in plasma concentrations of hormones and cytokines with CE in BAT^+^ and BAT^−^ subjects. *A*: Change in plasma norepinephrine levels with CE in BAT^+^ and BAT^−^ individuals. *B*: Change in plasma FGF21 concentrations with CE in BAT^+^ and BAT^−^ individuals. Change in plasma FT3 (*C*) and plasma FT4 (*D*) concentrations with CE in BAT^+^ and BAT^−^ individuals. *E*: Change in plasma irisin concentration with CE in BAT^+^ and BAT^−^ individuals. *F*: Change in serum IL-6 concentrations with CE in BAT^+^ and BAT^−^ individuals. Data are mean ± SEM. \**P* \< 0.05 and \*\**P* \< 0.01, significant difference in response to CE between BAT^+^ and BAT^−^ subjects.](4089fig5){#F5}

Molecular and Functional Characterization of BAT {#s23}
------------------------------------------------

The assignment of subjects into the BAT^+^ and BAT^−^ groups was based on the cold-induced glucose uptake in the supraclavicular region as assessed by PET/CT scanning. The reason for the low supraclavicular glucose uptake in the BAT^−^ group could be due to the fact that this group had less BAT. Alternatively, the BAT^−^ group might have had comparable amounts of BAT, relative to the BAT^+^ group, but was unable to activate it in response to the cold stimulus used (i.e., their threshold for cold-induced activation of BAT may have not been reached). To address the question of whether BAT^−^ subjects had BAT or not, we performed molecular and functional studies on adipose tissue samples collected from the supraclavicular depot by the guidance of the PET/CT scan images, and compared them with abdominal subcutaneous adipose tissue samples.

BAT^+^ subjects had UCP1-positive multilocular adipocytes in the supraclavicular tissue ([Fig. 6*A*](#F6){ref-type="fig"}), whereas the corresponding tissue of the BAT^−^ subjects demonstrated minimal UCP1 staining and was composed of largely unilocular adipocytes ([Fig. 6*B*](#F6){ref-type="fig"}). The abdominal subcutaneous adipose tissue samples were similar between the two groups, comprising unilocular adipocytes with no UCP1 staining ([Fig. 6*C* and *D*](#F6){ref-type="fig"}). Quantification of the UCP1 staining confirms these results (supraclavicular adipose tissue BAT^+^ vs. BAT^−^, *P* = 0.06) ([Fig. 6*E*](#F6){ref-type="fig"}). In agreement with the results from the immunohistochemical analysis, *UCP1* gene expression was higher in the supraclavicular adipose tissue from the BAT^+^ group relative to the BAT^−^ group (*P* = 0.06) ([Fig. 6*F*](#F6){ref-type="fig"}) and at a similar level as in a well-documented BAT control sample included in the analysis. No *UCP1* expression was detected in the abdominal subcutaneous adipose tissue samples. The molecular studies were complemented with functional studies showing that the maximal uncoupled mitochondrial respiration was significantly higher in the supraclavicular adipose tissue compared with the subcutaneous abdominal adipose tissue (*P* \< 0.05) only in the BAT^+^ group ([Fig. 6*G*](#F6){ref-type="fig"}). These results show that only the supraclavicular adipose tissue from the BAT^+^ group presents with features of BAT, whereas this is not the case for the BAT^−^ group. Hence, the low glucose uptake in the BAT^−^ group is due to a lower BAT content rather than a failure to activate BAT.

![Molecular and functional characterization of supraclavicular and abdominal subcutaneous adipose tissue samples in BAT^+^ and BAT^−^ subjects under conditions of cold-induced BAT. UCP1 staining (×40) in the supraclavicular (*A* and *B*) and abdominal (ABD) subcutaneous (*C* and *D*) adipose tissue samples from representative BAT^+^ (*A* and *C*) and BAT^−^ (*B* and *D*) participants. *E*: Quantification of UCP1 staining in supraclavicular (SC) and ABD subcutaneous adipose tissue. *F*: *UCP1* gene expression in SC and ABD subcutaneous adipose tissue. *G*: Uncoupled mitochondrial respiration in SC and ABD subcutaneous adipose tissue. Data are mean ± SEM. White circles, BAT^−^; black circles, BAT^+^. \**P* \< 0.05. *H*: *UCP1* gene expression in BAT under TN and CE conditions. Data are mean ± SD. \*\*\**P* \< 0.005. *I*: *DIO2* gene expression in BAT under TN and CE conditions. Data are mean ± SD. \*\*\**P* \< 0.005.](4089fig6){#F6}

To further examine how CE affects human BAT on a molecular level, biopsy samples were taken under both TN and CE conditions in a subset of BAT^+^ subjects. As predicted by animal studies on bona fide BAT, CE induced the expression of both *UCP1* and *DIO2* (type 2 deiodinase) ([Fig. 6*H* and *I*](#F6){ref-type="fig"}). In addition, CE induced the expression of *ADRB3* (β3-adrenergic receptor) and *PGC1α* (peroxisome proliferator--activated receptor γ coactivator 1α) ([Supplementary Figs. 3 and 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0746/-/DC1)). Hence, CE appears to trigger the expression of essential thermogenic genes in humans. The expression of the *GLUT1* gene increased with CE in three of four subjects, while *GLUT4* gene expression increased in two of four participants ([Supplementary Figs. 5 and 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0746/-/DC1)).

Discussion {#s24}
==========

We have shown a physiologically significant effect of BAT activation on whole-body glucose disposal in humans, supporting a functional role of BAT in glucose homeostasis and insulin sensitivity in humans. Our data suggest that ∼70 mL of active BAT can clear significant amounts of glucose from the circulation. This glucose is used to support the cold-induced increase in REE in the BAT^+^ group. Further, this was accompanied by an increase in peripheral insulin-stimulated glucose disposal in BAT^+^ individuals. Our data demonstrate a significant role for BAT activation in altering glucose control and insulin sensitivity in humans.

Plasma glucose oxidation accounted for ∼30% of the estimated increase in REE during CE in BAT^+^ subjects. This estimate is consistent with results from animal studies ([@B32]). Plasma FFA oxidation was responsible for the remaining 70% of the increase in REE. This is also in agreement with animal data suggesting that FFAs represent the primary substrate oxidized by UCP1-positive mitochondria ([@B32]). Our findings of significant plasma substrate use by BAT upon activation are in contrast with a recent report that BAT uses mainly intracellularly stored triacylglycerols and very few, if any, plasma substrates ([@B12]). This may be due to the short (2.5 h) duration of CE in this study ([@B12]) compared with that in our longer CE protocol (5 h). This supposition is supported by rodent data, which indicate that BAT first exhausts intracellular stores before relying on plasma-borne substrates to support its energy needs ([@B8]). Therefore, we believe that our results differ from those previously reported ([@B12]) due to our CE protocol being two times longer. The duration of CE should be a consideration for future studies aimed at elucidating the role of BAT activation in human metabolism.

BAT is an insulin-sensitive tissue ([@B11]). Moreover, because humans spend a significant portion of the day in the postprandial state, we examined the effect of cold-induced BAT activation during a hyperinsulinemia-euglycemia clamp to simulate the postprandial state in a laboratory setting. Hyperinsulinemia significantly increased whole-body glucose disposal and insulin sensitivity in the BAT^+^ group only. These results suggest that BAT activation may modulate whole-body glucose metabolism in the postprandial state. Moreover, relative to the TN study, CE improved indexes of insulin sensitivity in the BAT^+^ group only, further supporting a role for BAT activation in whole-body insulin sensitivity in humans.

Although we cannot exclude the contribution of indirect pathways in the observed increase in the insulin-stimulated whole-body glucose uptake, we believe that the increase was due to BAT activation and not a systemic response to CE. This is supported by the fact that hyperinsulinemia during thermoneutrality increased whole-body glucose uptake equally in both groups, whereas hyperinsulinemia during CE increased glucose uptake only in the BAT^+^ group. Moreover, we performed a low-dose insulin clamp to avoid significant muscle glucose uptake. Further, it is unlikely that muscle glucose uptake was proceeding at a significant rate, as CE causes peripheral vasoconstriction ([@B33]), which has been shown to decrease peripheral insulin-stimulated glucose uptake ([@B34]). Indeed, CE has been found to preferentially enhance insulin signaling in BAT, and to perturb insulin signaling in muscle and WAT ([@B35]), suggesting that BAT is likely the tissue primarily responsible for the reported improvements in insulin sensitivity during CE.

Norepinephrine also induces BAT activation by causing lipolysis ([@B8]). FFAs subsequently bind to and activate UCP1, leading to mitochondrial thermogenesis ([@B8]). We observed greater norepinephrine levels in response to CE in the BAT^+^ subjects, which was likely responsible for the increase in REE observed in the BAT^+^ group. Moreover, norepinephrine production can stimulate BAT to produce FGF21 ([@B36]). FGF21 improves glucose homeostasis and insulin sensitivity by increasing *GLUT1* expression in WAT. A number of animal studies ([@B8],[@B10]) and a few recent humans studies support a role for BAT as an endocrine tissue ([@B37]). In agreement with this, CE induced greater increases in circulating levels of FT3, norepinephrine, and FGF21 in the BAT^+^ group compared with the BAT^−^ group in the current study. Thus, the reported improvement in insulin sensitivity in BAT^+^ subjects may be attributable to circulating levels of FGF21 during CE. Adrenergic stimulation and FT3 are upstream regulators of FGF21 production. Therefore, the concomitant increase in FT3 and norepinephrine levels highlights a plausible pathway by which BAT may function as an endocrine organ. Specifically, CE increases DIO2 activity in BAT, resulting in an acceleration in the conversion of thyroxin to triiodothyronine, the active form of thyroid hormone ([@B38]). Indeed, our results also show increased *DIO2* expression in BAT upon CE. In mice, triiodothyronine stimulates the sympathetic nervous system, leading to higher *UCP1* expression in BAT ([@B30]).

The strengths of this study include the use of an individualized, prolonged nonshivering CE protocol to elicit maximal nonshivering thermogenesis and BAT activation, along with the use of gold standard direct measures of whole-body glucose metabolism in individuals with or without active BAT depots. Although the methodological approaches available and the restrictions governing human research limit our ability to provide more direct and mechanistic evidence, the results of this study strongly support the idea that BAT activation plays a physiologically significant role in whole-body glucose and energy metabolism in humans. The use of invasive methodologies to directly measure substrate metabolism and collect supraclavicular biopsy samples from human volunteers allow physiologically meaningful conclusions to be made.

In conclusion, our results suggest that BAT activation increases whole-body glucose disposal and insulin sensitivity in humans. These results support a functional role of BAT in whole-body glucose and energy homeostasis. Future research is needed to further investigate the effect of chronic BAT activation and the mechanisms underlying BAT activation in humans to identify safe and efficacious lifestyle or pharmaceutical interventions that may activate BAT in vivo or induce the "browning" of the more abundant WAT. If the potential of UCP1-positive adipocytes to alter energy metabolism and expenditure in humans can be fully realized, BAT will likely emerge as a therapeutic target in the battle against obesity and diabetes.
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